Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2019-12-31 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Total number of shares and voting rights in Zealand Pharma at December 31, 2019
Share Issue/Capital Change Classification · 95% confidence The document is a formal company announcement regarding the total number of shares and voting rights following a change in share capital due to the exercise of employee warrants. This type of disclosure is a standard regulatory requirement for listed companies to update the market on their capital structure. Among the provided categories, 'Share Issue/Capital Change' (SHA) is the most accurate fit as it specifically covers announcements regarding new share issues and capital changes.
2019-12-31 English
Total number of shares and voting rights in Zealand Pharma at December 31, 2019
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory announcement regarding the total number of shares and voting rights in Zealand Pharma as of December 31, 2019. This type of disclosure is required under Danish law when there are changes to share capital. While it mentions share capital, it is a standard regulatory disclosure of share counts rather than a primary capital raise or a major shareholding notification (MRQ). Given the nature of the disclosure regarding share capital changes and the regulatory requirement, it fits best under the 'Share Issue/Capital Change' category.
2019-12-31 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs), specifically detailing a sale of shares by an executive (Adam Sinding Steensberg) of Zealand Pharma A/S. This falls directly under the definition of 'Director's Dealing' (Code: DIRS), which covers personal share transactions by company directors and executives.
2019-12-13 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is titled 'Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities'. This is a standard disclosure for insider trading or director dealings. Although it mentions an attached file, the primary purpose of the announcement is to report these specific transactions by management, which aligns perfectly with the 'Director's Dealing' (DIRS) category.
2019-12-13 English
Director's Dealing 2019
Director's Dealing Classification · 100% confidence The document title explicitly states: "Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons." This directly corresponds to the definition of Director's Dealing (insider trades by management). The document is a short announcement (2812 chars) that directs the reader to an attached file for the details, fitting the pattern of an announcement rather than the full report itself. Therefore, the most specific classification is DIRS (Director's Dealing).
2019-12-13 English
Zealand Pharma partner Beta Bionics receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Beta Bionics has received FDA Breakthrough Device designation for its iLet Bionic Pancreas System. It describes the technology, the regulatory milestone, and provides company background. Since it does not fit into specific financial reporting categories like 10-K, ER, or IR, and is a general corporate announcement regarding regulatory status, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements.
2019-12-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.